These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 23414100)

  • 1. Rituximab in renal transplantation.
    Barnett AN; Hadjianastassiou VG; Mamode N
    Transpl Int; 2013 Jun; 26(6):563-75. PubMed ID: 23414100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Late-onset neutropenia and acute rejection in ABO-incompatible kidney transplant recipients receiving rituximab and mycophenolate mofetil.
    Kabei K; Uchida J; Iwai T; Yamasaki T; Kuwabara N; Naganuma T; Kumada N; Nakatani T
    Transpl Immunol; 2014 Aug; 31(2):92-7. PubMed ID: 24932811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy and safety of high-dose mizoribine in ABO-incompatible kidney transplantation using anti-CD20 and anti-CD25 antibody without splenectomy treatment.
    Yoshimura N; Ushigome H; Matsuyama M; Nobori S; Suzuki T; Sakai K; Okajima H; Okamoto M
    Transplant Proc; 2012 Jan; 44(1):140-3. PubMed ID: 22310599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of 2 Doses of Rituximab on B-Cell and Antidonor Antibody and Outcomes of ABO-Incompatible Living-Donor Pediatric Kidney Transplant.
    Hamasaki Y; Aikawa A; Itabashi Y; Muramatsu M; Hyoudou Y; Shinoda K; Takahashi Y; Sakurabayashi K; Mizutani T; Oguchi H; Kawamura T; Sakai K; Shishido S
    Exp Clin Transplant; 2019 Jan; 17(Suppl 1):105-109. PubMed ID: 30777532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tailored desensitization strategies in ABO blood group antibody incompatible renal transplantation.
    Barnett AN; Manook M; Nagendran M; Kenchayikoppad S; Vaughan R; Dorling A; Hadjianastassiou VG; Mamode N
    Transpl Int; 2014 Feb; 27(2):187-96. PubMed ID: 24188566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-CD20 monoclonal antibody treatment of Epstein-Barr virus-induced intrahepatic lymphoproliferative disorder following liver transplantation.
    Yedibela S; Reck T; Niedobitek G; Gramatzki M; Repp R; Hohenberger W; Ott R
    Transpl Int; 2003 Mar; 16(3):197-201. PubMed ID: 12664216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful use of anti-CD20 monoclonal antibody (rituximab) for ABO-incompatible living-related liver transplantation.
    Usuda M; Fujimori K; Koyamada N; Fukumori T; Sekiguchi S; Kawagishi N; Akamatsu Y; Enomoto Y; Satoh K; Satoh A; Ishida K; Moriya T; Satomi S
    Transplantation; 2005 Jan; 79(1):12-6. PubMed ID: 15714163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neither pre-transplant rituximab nor splenectomy affects de novo HLA antibody production after renal transplantation.
    Ashimine S; Watarai Y; Yamamoto T; Hiramitsu T; Tsujita M; Nanmoku K; Goto N; Takeda A; Katayama A; Uchida K; Kobayashi T
    Kidney Int; 2014 Feb; 85(2):425-30. PubMed ID: 23945498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Different Rituximab Doses on B Cell Count, Anti-A/B Antibody Titer, Graft Function, and Infectious Complications in ABO-Incompatible Renal Transplantation: A Prospective Study.
    Thukral S; Shinde N; Ray DS
    Transplant Proc; 2021 Apr; 53(3):970-975. PubMed ID: 33279260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The 5-year outcome of ABO-incompatible kidney transplantation with rituximab induction.
    Fuchinoue S; Ishii Y; Sawada T; Murakami T; Iwadoh K; Sannomiya A; Koyama I; Kubota K; Tojimbara T; Nakajima I; Teraoka S
    Transplantation; 2011 Apr; 91(8):853-7. PubMed ID: 21297552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results of a multicenter prospective clinical study in Japan for evaluating efficacy and safety of desensitization protocol based on rituximab in ABO-incompatible kidney transplantation.
    Takahashi K; Saito K; Takahara S; Fuchinoue S; Yagisawa T; Aikawa A; Watarai Y; Yoshimura N; Tanabe K; Morozumi K; Shimazu M;
    Clin Exp Nephrol; 2017 Aug; 21(4):705-713. PubMed ID: 27534951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pinpoint targeted immunosuppression: anti-CD20/MMF desensitization with anti-CD25 in successful ABO-incompatible kidney transplantation without splenectomy.
    Saito K; Nakagawa Y; Suwa M; Kumagai N; Tanikawa T; Nishiyama T; Ueno M; Gejyo F; Nishi S; Takahashi K
    Xenotransplantation; 2006 Mar; 13(2):111-7. PubMed ID: 16623803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of rituximab dosage for ABO-incompatible living-donor kidney transplantation.
    Nakao T; Ushigome H; Kawai K; Nakamura T; Harada S; Koshino K; Suzuki T; Ito T; Nobori S; Yoshimura N
    Transplant Proc; 2015 Apr; 47(3):644-8. PubMed ID: 25891703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ABO-incompatible live donor renal transplantation using blood group A/B carbohydrate antigen immunoadsorption and anti-CD20 antibody treatment.
    Nordén G; Briggs D; Cockwell P; Lipkin G; Mjörnstedt L; Mölne J; Ready A; Rydberg L; Samuelsson O; Svalander CT; Breimer ME
    Xenotransplantation; 2006 Mar; 13(2):148-53. PubMed ID: 16623810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful A1-to-O ABO-incompatible kidney transplantation after a preconditioning regimen consisting of anti-CD20 monoclonal antibody infusions, splenectomy, and double-filtration plasmapheresis.
    Sawada T; Fuchinoue S; Teraoka S
    Transplantation; 2002 Nov; 74(9):1207-10. PubMed ID: 12451255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ABO-incompatible kidney transplantation.
    Schousboe K; Titlestad K; Baudier F; Hansen LU; Bistrup C
    Dan Med Bull; 2010 Oct; 57(10):A4197. PubMed ID: 21040684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between response to rituximab and antibody-mediated rejection in ABO-incompatible living kidney transplantation.
    Maenosono R; Unagami K; Kakuta Y; Furusawa M; Okumi M; Azuma H; Ishida H; Tanabe K
    Int J Urol; 2019 Dec; 26(12):1114-1120. PubMed ID: 31522467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longitudinal analysis of T and B cell phenotype and function in renal transplant recipients with or without rituximab induction therapy.
    Kamburova EG; Koenen HJ; van den Hoogen MW; Baas MC; Joosten I; Hilbrands LB
    PLoS One; 2014; 9(11):e112658. PubMed ID: 25393622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-CD20 monoclonal antibody (Rituximab) treatment for Epstein-Barr virus-associated, B-cell lymphoproliferative disease in pediatric liver transplant recipients.
    Serinet MO; Jacquemin E; Habes D; Debray D; Fabre M; Bernard O
    J Pediatr Gastroenterol Nutr; 2002 Apr; 34(4):389-93. PubMed ID: 11930095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequent development of subclinical chronic antibody-mediated rejection within 1 year after renal transplantation with pre-transplant positive donor-specific antibodies and negative CDC crossmatches.
    Yamanaga S; Watarai Y; Yamamoto T; Tsujita M; Hiramitsu T; Nanmoku K; Goto N; Takeda A; Morozumi K; Katayama A; Saji H; Uchida K; Kobayashi T
    Hum Immunol; 2013 Sep; 74(9):1111-8. PubMed ID: 23792054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.